Introduction
============

Drug response is likely a multi-genic trait with numerous genes playing a role in drug response and toxicity. Scientists are beginning to appreciate the daunting level of complexity in the search for genes associated with drug response and/or toxicity. Predicting which patients will respond or experience an adverse effect would be highly beneficial to medicine. One reason is that adverse drug reactions (ADRs) have become one of the leading causes of hospitalization and death in the United States, accounting for more than 2.2 million serious cases and over 100,000 deaths a year estimated in a meta-analysis study ([@b44-pgpm_1_7]). Understandably, personalization of medical treatment would help to prevent this by identifying those individuals at greatest risk for toxicity prior to therapy ([@b54-pgpm_1_7], [@b55-pgpm_1_7]).

There are several examples of the personalized medical approach, which include genotype-based selection of patients for effective therapy, to spare those who would not respond or would suffer undesirable side effects ([@b38-pgpm_1_7]). To fully understand the risk for a given patient, whole-genome data would be most comprehensive; however we are not yet at the point of translating that information into dosing recommendations ([@b55-pgpm_1_7]). The challenge is that drug response is influenced by many different genetic and nongenetic factors and the extent to which each factor contributes to variation in response is not yet fully understood making the development of diagnostic tests that could predict an individual's response to a particular drug difficult.

During the past decade or so, equipped with the human whole-genome sequences ([@b43-pgpm_1_7]; [@b70-pgpm_1_7]) and high throughput genotying technologies (eg, sequencing, microarrays) ([@b13-pgpm_1_7]; [@b68-pgpm_1_7]; [@b58-pgpm_1_7]), exciting progress has been made in understanding the contribution of human genetic variations, especially in the form of single nucleotide polymorphisms (SNPs), to how individuals respond to medications, either by changing the pharmacokinetics of drugs or by altering the cellular response to therapeutic agents ([@b57-pgpm_1_7]; [@b76-pgpm_1_7]; [@b24-pgpm_1_7]; [@b29-pgpm_1_7]; [@b69-pgpm_1_7]; [@b82-pgpm_1_7]). Examples include recent studies using a candidate gene approach ([@b45-pgpm_1_7]; [@b39-pgpm_1_7]; [@b59-pgpm_1_7]) or a whole-genome analysis ([@b33-pgpm_1_7], [@b34-pgpm_1_7]; [@b81-pgpm_1_7]) to identify genetic variants that are correlated with cytotoxicity to anticancer agents. In addition to SNPs, other genetic elements such as DNA copy number variants (CNVs) have been implicated in drug response ([@b10-pgpm_1_7]; [@b26-pgpm_1_7]). The association studies aim to link genetic variation, either in the form of SNPs or CNVs (both causal or as markers) to expression of targeted gene(s), which in turn may determine, in part, the variation in individual response to drugs. However, not only DNA sequence-based variations (SNPs and CNVs) can affect gene expression, other nongenetic factors such as environment/habitat ([@b37-pgpm_1_7]) and epigenetic status ([@b84-pgpm_1_7]) can also regulate gene expression *in vivo*, suggesting the potential roles of these nongenetic factors in determining variation in drug response ([Figure 1](#f1-pgpm_1_7){ref-type="fig"}). Furthermore, environmental factors have been shown to affect epigenetic status ([@b72-pgpm_1_7]). For example, [@b42-pgpm_1_7] reviewed the role of botanicals in epigenetic modulation. The effects of soy foods and exposure to genistein (a soy isoflavone) in breast cancer risk reduction have also been discussed ([@b74-pgpm_1_7]). Recent studies suggest that epigenetic regulation may in part mediate the complex gene-by-environment interactions that can lead to asthma ([@b46-pgpm_1_7]) and other diseases ([@b16-pgpm_1_7]). Though three mechanisms, including CpG methylation, histone modification and RNA-associated silencing ([@b5-pgpm_1_7]; [@b32-pgpm_1_7]; [@b19-pgpm_1_7]), have been defined as epigenetic modifiers, this review will focus on DNA methylation at CpG sites, which is currently the most well understood eukaryotic epigenetic modification, due to the availability of high throughput technology such as the Affymetrix ChIP-on-chip ([@b85-pgpm_1_7]; [@b4-pgpm_1_7]), the Illumina BeadArray platform ([@b7-pgpm_1_7]; [@b37-pgpm_1_7]) and the Roche NimbleGen arrays ([@b75-pgpm_1_7]).

Methylation at CpG sites can be an accurate proxy for other epigenetic marks, such as histone methylation and acetylation (Lippman et al 2004; [@b83-pgpm_1_7]). DNA methylation can be either *de novo* (when CpG sites on both DNA strands are unmethylated) or maintenance (when CpG sites on one strand are methylated). Methylation of the C^5^ of cytosine residues in DNA has long been recognized as a fundamental epigenetic silencing mechanism ([@b30-pgpm_1_7]; [@b31-pgpm_1_7]). 5-methylcytosine is also highly mutagenic, causing higher mutation rates at CpG sites for both transitions and transversions ([@b78-pgpm_1_7]). Given the critical role of DNA methylation in regulating gene expression, we suggest that genome-wide profiling of epigenetic variation (methylome) and association studies using these epigenomic data will provide new insights into gene regulation and individual drug response at a higher level of complexity relative to the current genetic variant-based pharmacogenomic studies. We suggest that the next wave of pharmacogenomic studies will have greater depth if both genetic variants and epigenetic variations are included in the analysis.

Gene expression, drug response, and DNA methylation
===================================================

Gene expression acts as an intermediate phenotype situated between genetic (eg, sequence variation in DNA) and nongenetic factors (eg, environmental stimuli) and other more complex cellular, tissue, organ or whole-organism phenotypes (eg, drug response). Numerous studies have shown that gene expression can affect susceptibility to drug response. For instance, a widely appreciated example is the multi-drug resistance exhibited by tumor cells to anticancer agents through over-expression of MDR genes ([@b49-pgpm_1_7]). Numerous recent studies have demonstrated the use of genomic data, particularly gene expression signatures, as clinical prognostic factors in cancer and other complex diseases ([@b22-pgpm_1_7]; [@b48-pgpm_1_7]). These studies have demonstrated that gene expression signatures have the capability of predicting response to various commonly used and newly developing cancer therapeutics ([@b51-pgpm_1_7]). For example, a recent study showed that incorporation of gene expression signatures into clinical risk stratification can refine prognosis in breast cancer ([@b2-pgpm_1_7]).

On one hand, quantitative variation in gene-expression level (eg, mRNA transcript abundance) as a complex trait is heritable and has been mapped to the human genome as expression quantitative trait loci (eQTLs) in LCLs including the HapMap samples ([@b47-pgpm_1_7]; [@b64-pgpm_1_7]; [@b66-pgpm_1_7]; [@b14-pgpm_1_7]; [@b80-pgpm_1_7]), which represent genomic regions marked by *cis*-acting or *trans*-acting SNPs for the genetic control of gene expression. Substantial contribution of DNA structural variation (eg, CNVs) ([@b56-pgpm_1_7]) to gene expression variation has also been demonstrated recently in the HapMap samples ([@b65-pgpm_1_7]), which include 210 individuals of major world populations in northern and western Europe (CEU, Caucasians from Utah, USA), Africa (YRI, Yoruba people from Ibadan, Nigeria) and Asia (JPT, Japanese from Tokyo, Japan; CHB, Han Chinese from Beijing, China) ([@b82-pgpm_1_7]). On the other hand, increased methylation in the promoter region of a gene has been shown to lead to reduced expression, whereas methylation in the transcribed region has a variable effect on gene expression ([@b40-pgpm_1_7]; [@b63-pgpm_1_7]). Thus DNA methylation patterns, together with SNPs or CNVs, likely play an important role in gene regulation, which in turn may affect drug response.

Integrating genetic variation, expression and sensitivity to drugs has been a focus of several recent studies. Both candidate gene approach ([@b45-pgpm_1_7]; [@b39-pgpm_1_7]; [@b59-pgpm_1_7]) or whole-genome associations ([@b33-pgpm_1_7], [@b34-pgpm_1_7]; [@b81-pgpm_1_7]) have been employed to identify genetic variants that are associated with both drug-induced cytotoxicity and gene expression. These studies did not integrate promoter methylation; however epigenetic regulation of gene expression could explain much of the variation that is not due to SNPs or CNVs and improve our understanding of the role of gene expression in drug response.

Though the roles of DNA methylation in diseases such as cancer have been a topic of considerable interest in the past few years ([@b12-pgpm_1_7]; [@b17-pgpm_1_7]; [@b61-pgpm_1_7]; [@b71-pgpm_1_7]), the relationship between variation in DNA methylation status and gene expression has just begun to be studied. In a pilot study of the Human Epigenome Project ([@b8-pgpm_1_7]), DNA methylation profiling (∼1.9 million CpG sites) of human chromosomes 6, 20 and 22 from 12 different tissues was performed ([@b15-pgpm_1_7]). A substantial fraction (∼17%) of genes were found differentially methylated in their 5' UTRs and about one-third of the differentially methylated 5' UTRs were inversely correlated with transcription even after controlling for factors reported to affect DNA methylation such as sex and age ([@b15-pgpm_1_7]). In the past few years, the roles of DNA methylation through regulating gene expression in drug response have also been investigated by various laboratories ([@b25-pgpm_1_7]; [@b9-pgpm_1_7]; [@b67-pgpm_1_7]). One example is the DNA repair enzyme *O*^6^-methylguanine DNA methyltransferase (*MGMT*) efficiency of which has been associated with an increased susceptibility to alkylating agent toxicity ([@b41-pgpm_1_7]; [@b23-pgpm_1_7]; [@b52-pgpm_1_7]). *MGMT* is transcriptionally silenced by promoter hypermethylation in several human cancers such as diffuse large B-cell lymphoma ([@b18-pgpm_1_7]) as well as head and neck squamous cell carcinoma ([@b87-pgpm_1_7]). In a retrospective cohort study, [@b18-pgpm_1_7] demonstrated that *MGMT* promoter hypermethylation appeared to be a useful marker for predicting survival in patients with diffuse large B-cell lymphoma treated with multidrug regimens including cyclophosphamide. The demethylation of *MGMT* promoter was also shown to be involved in basic fibroblast growth factor--induced resistance against temozolomide in human melanoma cells ([@b20-pgpm_1_7]). More recently, [@b62-pgpm_1_7] assessed DNA methylation of 32 promoter-associated CpG islands in human cancer cell lines from the National Cancer Institute (NCI) drug-screening panel (NCI-60 panel). By correlating drug activity with DNA methylation, they identified a list of methylation markers that predicted sensitivity to chemotherapeutic drugs. For example, hypermethylation of the *TP53* homologue *TP73* and associated gene silencing was strongly correlated with sensitivity to alkylating agents. The methylation status of tumor suppressor genes (*TIMP3*, *APC*, and *IGSF4*) in the NCI-60 panel has also been found significantly correlated with the sensitivity to some antimetabolites such as fluorouracil (5-FU) ([@b60-pgpm_1_7]). In another study, [@b27-pgpm_1_7] showed a significant effect of methylation status of *P15*, *CDH* (E-cadherin) and *HIC* (hypermethylated in cancer 1) genes on the outcome of conventional chemotherapy in high-risk myelodysplastic syndromes (MDS) and acute myelogenous leukemia following MDS. Though the current studies using patients or patient-derived cell lines (eg, the NCI-60 panel) have shown the potential roles of DNA methylation of some candidate genes in drug response and cytotoxicity, the relationship between DNA methylation status of genes (not only candidate genes like tumor suppressors or *MGMT*) with drug resistance or sensitivity have not been comprehensively investigated.

Overall, these studies suggest that the variation in DNA methylation status can significantly contribute to the variation in gene expression, which in turn may affect drug response. [Figure 2](#f2-pgpm_1_7){ref-type="fig"} shows a possible scenario for the relationship between DNA methylation and gene expression as well as drug response in a population. Similar to other genetic factors, cytosine methylation patterns are also heritable through cell division. Their preservation involves the "maintenance" methyltransferase DNMT1, which has specificity for hemi-methylated CpG dinucleotides; the enzyme thus can methylate CpGs in a newly synthesized DNA strand based on the presence of methylation in the CpG dinucleotide in the complementary template strand ([@b6-pgpm_1_7]). Therefore, this kind of epigenetic inheritance may allow cells of different phenotype (eg, drug response) but identical genotype to transmit their phenotype to their offspring. Although many genes have been identified that acquire methylation and whose expression is methylation-sensitive, little is known about how DNA methylation is controlled ([@b77-pgpm_1_7]). Our current knowledge suggest DNA methylation may be regulated by different variants of DNA methyltransferase ([@b73-pgpm_1_7]) or *RASGRF1* (a Ras protein-specific guanine nucleotide-releasing factor 1) ([@b77-pgpm_1_7]). At present we have very poor understanding of the factors that contribute to interindividual epigenetic variation. The effects of DNA methylation status on gene regulation can be independent of those based on genetic variations (eg, SNPs), suggesting that the availability of a high-resolution DNA methylation resource could add another layer of information to our understanding of how genetic and epigenetic variation could be used in pharmacogenomic studies.

Whole-genome approaches to profiling DNA methylation
====================================================

Recent progress in biotechnology has provided tools to detect DNA methylation in the human genome, thus potentially allowing the study of the roles of DNA methylation in gene regulation. DNA methylation can be detected using bisulfite conversion, methylation-sensitive restriction enzyme (MSRE) digestion, methyl-binding proteins and anti-methylcytosine antibodies. Combining these techniques with DNA microarrays and high-throughput sequencing has made the mapping of DNA methylation feasible on a genome-wide scale ([@b86-pgpm_1_7]).

Bisulfite conversion is based on treatment of DNA with bisulfite, a chemical that results in the conversion of cytosine to uracil, but leaves 5-methylcytosine residues unaffected, thus introducing specific changes (C to T transitions) in the DNA sequence that depend on the methylation status of cytosine residues. The methylation status then can be deduced by techniques such as direct sequencing ([@b21-pgpm_1_7]; [@b15-pgpm_1_7]), pyrosequencing ([@b11-pgpm_1_7]) or microarray-based methods ([@b1-pgpm_1_7]), which can be used in a genome-wide analysis of DNA methylation. For the latter, microarrays can be designed using oligonucleotide pairs targeting CpG sites of interest, with one complementary to the unaltered methylated sequence, and the other to the C-to-T converted unmethylated sequence ([@b3-pgpm_1_7]). As the name implies, the method of MSRE digestion uses methylation specific restriction enzymes such as *Hpa*II to cleave DNA at specific methylated-cytosine residues. Similarly, whole-genome oligonucleotide microarrays then can be used to differentiate the MSRE-digested products and background (eg, DNA fragments digested by nonmethylation-sensitive restriction enzymes such as *Msp*I) ([@b84-pgpm_1_7]). In contrast, the methods based on methyl-binding proteins and anti-methylcytosine antibodies use specific methyl-group binding proteins or methylcytosine antibodies to enrich methylated DNA fragments through chromatin immunoprecipitation (ChIP) ([@b85-pgpm_1_7]). Again, whole-genome oligonucleotide microarrays can be used to analyze the methylation status of the ChIP products.

In spite of some limitations, for example, the coverage of the MSRE digestion approach is limited to the CpG sites ([@b84-pgpm_1_7]); and incomplete conversion and degradation of DNA during bisulfite treatment could be confounding factors for the bisulfite conversion approach ([@b28-pgpm_1_7]). These approaches have begun to allow genome-wide analyses of DNA methylation in humans ([@b15-pgpm_1_7]). For example, in a previously mentioned study, using the bisulfite sequencing approach, the CpG methylation profiles of 43 samples derived from 12 different human tissues (eg, heart muscle, skeletal muscle) and various primary cell types (eg, dermal fibroblasts, CD4+ and CD8+ lymphocytes) were determined for chromosomes 6, 20, and 22 ([@b15-pgpm_1_7]). Obviously, these whole-genome or epigenomic approaches provide promising tools to profile the variation in DNA methylation as well as to illustrate the relationship between DNA methylation and gene expression.

Conclusions and outlook
=======================

The realization of personalized medicine promises better treatment regimens for individuals based on the information contained in the human genome. To date, most pharmacogenomic studies have focused on the contribution of common genetic variants (SNPs and CNVs) to individual response to therapeutic treatments. However, nongenetic factors such as the epigenetic systems could also play an important role in gene regulation, which in turn could affect drug response. DNA methylation is currently the best-understood epigenetic system ([@b19-pgpm_1_7]). In the past few years, whole-genome DNA methylation profiling has become possible benefiting from the combination of methylation-specific and microarray-based techniques. Given the fact that common genetic variants only account for a fraction of the variation in drug response, other mechanisms such as DNA methylation status could help explain the remaining variation in drug response. We envision that in an ideal world, treatment decisions would be based on an individual's whole-genome information which includes both genetic and nongenetic factors including DNA methylation status. A more comprehensive view of the genome that includes epigenetic information will also provide information on the use of agents aimed at pathways important in DNA methylation and gene regulation ([@b50-pgpm_1_7]).

Research efforts such as the Human Epigenome Project, which aims to identify, catalog and interpret genome-wide DNA methylation profiles of all human genes in all major tissues ([@b8-pgpm_1_7]; [@b53-pgpm_1_7]; [@b15-pgpm_1_7]), no doubt will provide new insights into the epigenetic components of the human genome and tissue specificity of epigenetic regulation of expression. However, integration of epigenomic profiling with resources such as those provided by the International HapMap Project ([@b35-pgpm_1_7], [@b36-pgpm_1_7]), which has genotypic data and various publicly available phenotypes that include gene expression (see the Gene Expression Omnibus, <http://www.ncbi.nlm.nih.gov/geo/>), drug response (see <http://www.PharmGKB.org>) on a panel of LCLs derived from major world populations ([@b82-pgpm_1_7]), will greatly facilitate the identification of both genetic and nongenetic determinants responsible for the response to therapeutic treatments. The HapMap LCLs have been used to build cell-based models for pharmacogenomic discovery but currently lacks epigenomic information. This information could be integrated with publicly available genotypic, gene expression and drug sensitivity data on the same cell line ([@b79-pgpm_1_7]). Additional tissues including the liver or skin should be considered for pharmacogenomic discovery by integrating genomic, epigenomic, expression and drug metabolism data. These models could be of great value to the pharmacogenomic community.
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![Both genetic and nongenetic factors can affect phenotypes. Phenotypes (eg, gene expression, drug response) can be affected by genetic variations (eg, SNPs), environmental factors as well as epigenetic changes (eg, DNA methylation). The arrows indicate possible interactions between factors.](pgpm_1_7f1){#f1-pgpm_1_7}

![DNA methylation status can affect variation in gene expression and drug response. **A**) For a particular drug response-related gene, there could be people with different epigenetic signatures within a population. Orange: sensitive people; Blue: nonrespondent people; white: all others. **B**) Sensitive people have an epigenetic signature that causes over-expression of the gene. **C**) In contrast, nonrespondent people have an epigenetic signature that inhibits gene expression.](pgpm_1_7f2){#f2-pgpm_1_7}
